Artelo Biosciences announced the publication of an article, “The emerging role of fatty acid binding protein 7 in cancers,” in Drug Discovery Today, a peer-reviewed journal. The article analyzes the results of various studies and presents a comprehensive analysis of FABP7’s role in a variety of cancers and its correlation with patient prognosis, as well as its potential utility as a validated target in cancer treatment. The publication reveals that FABP7, an intracellular protein involved in the uptake, transportation, metabolism, and storage of fatty acids, is upregulated in several cancers including breast, brain, and kidney cancers and is generally associated with a poor patient prognosis. Additionally, the evidence shows that both genetic and pharmacological inhibition of FABP7 led to reduced tumor cell growth, migration, and invasion in multiple studies. Moreover, inhibition of FABP7 improved host survival rates, particularly in brain cancers, indicating its role as a novel target in cancer.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARTL:
- Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy
- Artelo Biosciences CEO to Appear on Benzinga All Access on April 23rd at Approximately 10:50 AM Eastern Time
- Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update
- Artelo Biosciences reports 2023 EPS ($3.14), consensus ($2.56)
- Artelo Biosciences Selected as a Finalist in Johnson & Johnson’s Innovation Challenge